Sirolimus in the Treatment of Refractory/Relapsed wAIHA
Warm Autoimmune Hemolytic Anemia
About this trial
This is an interventional treatment trial for Warm Autoimmune Hemolytic Anemia focused on measuring warm autoimmune hemolytic anemia, Evans syndrome, refractory/relapsed, sirolimus, efficacy
Eligibility Criteria
Inclusion Criteria: Age ≥18 years old. Diagnosed as primary warm autoimmune hemolytic anemia or Evans syndrome (primary or secondary). There is no treatment indication of other systemic involvement in the original disease if secondary. No response to glucocorticoid therapy or recurrence. Baseline liver (ALT, AST) was less than 2 times the normal value. No active infection; Not pregnant or breastfeeding. Agree to sign the consent form. Exclusion Criteria: Patients with connective tissue disease or other organs involvement Infection or bleeding that cannot be controlled by standard treatment. Active HIV, HCV or HBV infection or cirrhosis or portal hypertension. Progressed uncontrolled malignant tumors and lymphoma Cirrhosis or portal hypertension. Pregnant or breastfeeding.
Sites / Locations
- Peking Union Medical College HospitalRecruiting
Arms of the Study
Arm 1
Experimental
Sirolimus on refractory/relapsed wAIHA
A prospective research of the sirolimus efficiency on refractory/relapsed primary wAIHA patients. Sirolimus dosage: 1-3 mg/d with plasma concentration 4-15ng/mL. Medication time should last at least 6 months. After reaching the optimal response, responders continue to use sirolimus for 1 year, and then gradually reduce the dosage.